## Is Argentina's RA-10 Research Reactor Finally Ready to Commission?

Argentina's 30-megawatt RA-10 open-pool multipurpose research reactor at the Ezeiza Atomic Centre is 96% complete, with the National Atomic Energy Commission (CNEA) and the Secretariat for Nuclear Affairs targeting the start of commissioning before the end of 2026 — contingent on receiving an operating licence from the country's Nuclear Regulatory Authority (ARN). Once operational, the reactor is expected to produce approximately 20% of total global demand for molybdenum-99 (Mo-99), the critical radioisotope that underpins the majority of nuclear medicine diagnostic procedures worldwide. A workforce of 530 people is currently on site completing final works and system tests ahead of the licensing milestone.

The commissioning announcement was made at a presentation led by Secretary of Nuclear Affairs Federico Ramos Napoli and CNEA President Martín Porro. Alongside the technical update, the pair outlined a public-private financing model for the associated radioisotope production plant — a structural shift that signals Buenos Aires is treating RA-10 not merely as a research asset but as a commercial export play in a global Mo-99 market characterised by few suppliers and high technological barriers to entry.

---

## What Is the RA-10 and Why Does It Matter?

The RA-10 is a 30 MWt open-pool research reactor designed and built primarily by Argentine nuclear technology firm Invap, acting as main contractor. The project was officially launched by CNEA in June 2010, received a construction licence from the ARN in November 2014, and civil works began in 2016. It will replace the RA-3, a 10 MWt pool-type reactor that has operated on the same Ezeiza site since 1967 — itself a long-running Mo-99 producer.

Beyond radioisotope production, the RA-10 facility encompasses the Argentine Neutron Beam Laboratory and the Laboratory for the Study of Irradiated Materials. The reactor will also enable neutron-doped silicon production for semiconductor and industrial applications, and will serve as a training and research platform. In scope and ambition, it is more akin to a national nuclear services hub than a traditional research reactor.

The Mo-99 angle is the commercially significant number here. Mo-99 decays into technetium-99m, the most widely used radiotracer in diagnostic imaging. Global supply has been chronically fragile — heavily concentrated among a small number of ageing reactors in Europe and Canada — and any new supplier capable of meeting roughly one-fifth of global demand represents a genuine structural shift for nuclear medicine supply chains. Argentina's CNEA has framed its planned capacity as exceeding domestic demand, explicitly targeting exports and the foreign exchange they would generate.

---

## Private Capital and the Production Plant Model

The more strategically interesting announcement from Ramos Napoli concerns financing. CNEA confirmed it is pursuing a model that will allow private capital to fund the development and construction of the associated radioisotope production plant, as well as the commercial activities tied to reactor output. The national government retains strategic leadership; regulatory oversight remains with the ARN.

This public-private structure is notable. Research reactors are typically state-funded infrastructure, with commercial radioisotope production bolted on. Argentina is instead architecturing the production side as an investable asset — a structure more familiar in pharmaceutical manufacturing than nuclear. Whether this attracts meaningful private capital will depend heavily on Argentina's broader sovereign risk environment, but the model itself reflects a growing global pattern of governments seeking to de-risk nuclear infrastructure through project finance rather than pure appropriation.

The CNEA framing — "few suppliers and high technological barriers" — is accurate and telling. Mo-99 production requires a neutron flux capable of irradiating molybdenum-98 targets, hot-cell processing infrastructure, and the logistics to deliver a radioisotope with a roughly 66-hour half-life to hospitals globally. Invap's involvement gives Argentina indigenous technical depth that few countries outside Europe, Canada, and Russia possess.

---

## Schedule Risk and What Comes Next

The commissioning target of before end of 2026 is conditional on ARN issuing a licence. With 530 workers completing final system tests, the technical trajectory appears credible — but regulatory timelines carry their own uncertainty independent of construction progress. The project has been under development since 2010; a 16-year development arc for a first-of-kind national research reactor is not unusual, but it does mean the commissioning clock has slipped before.

The [first-of-a-kind (FOAK)](https://smrintel.com/glossary/foak) nature of RA-10 at this scale for Argentina also means that commissioning itself — the phased approach to achieving first criticality, power ascension testing, and operational qualification of the production facilities — will take time beyond the licence grant. Commercial Mo-99 production at scale should not be assumed to follow immediately on commissioning.

For the broader advanced reactor and research reactor community, RA-10 is a proof point that mid-tier nuclear nations can develop commercially relevant reactor infrastructure indigenously. Invap already has an established export track record in research reactors. A successful RA-10 commissioning strengthens that case and positions Argentina as a potential competitor — or partner — in future research reactor export markets.

---

## Key Takeaways

- **30 MWt, 96% complete:** Argentina's RA-10 at Ezeiza is in final system testing with 530 workers on site; commissioning targeted before end of 2026 pending ARN licence.
- **~20% of global Mo-99 demand:** RA-10's planned radioisotope output would make Argentina a major supplier in a thin, fragile global market.
- **Private capital model:** CNEA is structuring the associated production plant to attract private financing while the government retains strategic control and ARN retains regulatory authority.
- **Invap as main contractor:** Argentina's indigenous nuclear technology firm leads design and construction, reinforcing the country's position as a research reactor export competitor.
- **Export orientation:** CNEA explicitly states planned capacity exceeds domestic demand, targeting foreign exchange earnings and skilled job creation.
- **RA-3 replacement:** RA-10 replaces the 10 MWt RA-3, operational since 1967, tripling thermal output on the same Ezeiza site.

---

## Frequently Asked Questions

**What is the RA-10 reactor and what will it produce?**
The RA-10 is a 30-megawatt open-pool multipurpose research reactor being built at Argentina's Ezeiza Atomic Centre. It is designed to produce radioisotopes — primarily molybdenum-99 for nuclear medicine — as well as neutron-doped silicon for industrial applications, and to support neutron beam research and nuclear training. CNEA expects it to supply approximately 20% of total global Mo-99 demand.

**When will Argentina's RA-10 reactor start operating?**
CNEA and the Secretariat for Nuclear Affairs are targeting the start of commissioning before the end of 2026, subject to receiving an operating licence from Argentina's Nuclear Regulatory Authority (ARN). The reactor is reported as 96% complete, with 530 personnel on site completing final works and system tests.

**Who built the RA-10 reactor?**
Argentine nuclear technology firm Invap served as the main contractor for the design and construction of the RA-10 reactor facility and related installations. The project has been managed by CNEA since its official start in June 2010, with a construction licence granted by ARN in November 2014 and civil works commencing in 2016.

**Why does Mo-99 supply matter globally?**
Molybdenum-99 decays into technetium-99m, the most widely used radiotracer in diagnostic nuclear medicine imaging. Global supply is concentrated among a small number of reactors, making the supply chain vulnerable to outages. A reactor capable of producing approximately 20% of global demand — as RA-10 is projected to — would represent a significant addition to supply security.

**How is Argentina financing the RA-10 production plant?**
The national government is pursuing a public-private model in which private capital can fund the development and construction of the associated radioisotope production plant and its commercial activities. The government retains strategic leadership while the ARN maintains regulatory and oversight authority. The specific financing structure or investors have not yet been publicly named.